International CML Foundation

International CML Foundation Improving outcomes for patients with CML globally. The International CML Foundation (iCMLf) is on a mission to improve outcomes for patients with CML, globally.

Founded by a dedicated group of hematologists, we are committed to ensuring every patient with CML, no matter where they are in the world, receives the best possible care. We foster international collaboration to elevate knowledge, enhance diagnostics, and drive ground-breaking research. As a charitable foundation with a global reach, we strive to empower physicians, researchers, patients and caregivers alike, in the collective pursuit of a cure. Join us and contribute to a world where a cure for CML is not just a hope, but a reality.

The iCMLf Regional Discussion Group Meetings are back for 2026. Join us to connect with CML experts and colleagues acros...
19/03/2026

The iCMLf Regional Discussion Group Meetings are back for 2026. Join us to connect with CML experts and colleagues across Latin America to explore key challenges in treatment and patient care.

📅 First session: April 16th
Topic: First line therapy in CML - Is imatinib still the best frontline treatment? (Debate format)

⏰ Start times:
Mexico City – 17:00
Bogotá – 18:00
Buenos Aires / Rio de Janeiro / Santiago – 20:00

🌎 Online | Open to physicians treating CML across Latin America
Spanish interpretation available

Register now: https://us02web.zoom.us/meeting/register/DfjRXISgQ4iLGfrcabQIpw #/registration

Join the conversation in the iCMLf Clinical Case Discussion ForumCML care is constantly evolving, and some of the most v...
19/03/2026

Join the conversation in the iCMLf Clinical Case Discussion Forum

CML care is constantly evolving, and some of the most valuable insights come from shared experience.

The iCMLf Clinical Case Discussion Forum brings together clinicians from around the world to exchange perspectives, explore complex cases, and learn from one another in real time.

Whether you have a challenging case, a question, or experience to contribute, your input helps strengthen global understanding and improve patient care.

👉 Join the discussion: https://buff.ly/40ign0F

New in the iCMLf Clinical Trials Hub. We’ve made it easier to find studies investigating new compounds, with clear categ...
17/03/2026

New in the iCMLf Clinical Trials Hub.

We’ve made it easier to find studies investigating new compounds, with clear categories for recruiting and upcoming trials, plus key information available at a glance.

Designed for clinicians, researchers, patients, and advocates, the hub brings global CML trial information together in one place - making it simpler to stay informed and identify opportunities.

Explore the updated hub and download the latest file here: https://www.cml-foundation.org/science-education/science-clinical-trials.html

Stay connected with the global CML community.Follow the International CML Foundation across all of our social channels f...
13/03/2026

Stay connected with the global CML community.

Follow the International CML Foundation across all of our social channels for the latest updates on research, education, events, and initiatives supporting people living with chronic myeloid leukemia around the world.

Join the conversation and be part of the global effort to improve CML care.

We hope to see you there!

Thank you.The iCMLf Climb for a Cure was never just about reaching the summit. It was about the community behind it.Than...
10/03/2026

Thank you.

The iCMLf Climb for a Cure was never just about reaching the summit. It was about the community behind it.

Thanks to the generosity of individuals and supporters around the world, the climb has now raised over $186,000 to support the global work of the International CML Foundation.

We're so grateful to all our partners who helped make this incredible journey possible - Terns, Novartis , Enliven, Ascentage, SAHMRI

To everyone who donated, sponsored the team, shared the campaign, or encouraged the climbers along the way, we are incredibly grateful.

Your support helps drive the collaboration, education, and research that continue to improve outcomes for people living with CML worldwide!

https://buff.ly/BL7oTvn

They did it!!On Saturday, the iCMLf Climb for a Cure team completed their challenge in the Andes after days of trekking ...
09/03/2026

They did it!!

On Saturday, the iCMLf Climb for a Cure team completed their challenge in the Andes after days of trekking at altitude and pushing themselves step by step to the top.

An extraordinary effort in support of a global mission: improving care and outcomes for people living with CML everywhere.

Thank you to everyone who supported the climb.

You can still donate and support the mission:
🔗 https://buff.ly/BL7oTvn

Thanks to our sponsors: Terns, Novartis, Enliven, Ascentage, SAHMRI

We’re delighted to have welcomed Novartis back as a supporting partner of the iCMLf Climb for a Cure 2026. Stefanie Gran...
07/03/2026

We’re delighted to have welcomed Novartis back as a supporting partner of the iCMLf Climb for a Cure 2026.

Stefanie Granado, Therapeutic Area Head, Oncology International at Novartis, said:

“Treatment innovation in CML is one of the great success stories of modern oncology, yet the journey is not complete. Supporting the iCMLf Climb for a Cure 2026 reflects our long-standing commitment to the global CML community and to collaborative efforts that continue to advance research, education and equitable care.”

Here are our selection of CML Papers for February curated by Prof. Tim Hughes.Highlights include:1️⃣ A plain language su...
06/03/2026

Here are our selection of CML Papers for February curated by Prof. Tim Hughes.
Highlights include:

1️⃣ A plain language summary of how the body processes a lower-dose nilotinib tablet (DanzitenTM) compared with the existing capsule (Tasigna)
Mauro M et al. Future Oncol, February 2026
https://buff.ly/H4cjZqx

2️⃣ Pregnancy-related adverse events with tyrosine kinase inhibitor use in chronic myeloid leukemia: A FAERS Pharmacovigilance analysis (2001 – 2024)
Faisal MS et al. Clin Lymphoma Myeloma Leuk, February 2026
https://buff.ly/Cs2yztv

3️⃣ The importance of bone marrow biopsy for chronic myeloid leukemia classification – a case report
Gonçalves NY et al. HJ Hematop, February 2026 – open access publication
https://buff.ly/OMlDnM9

4️⃣ High miR-202-5p expression at initial diagnosis is associated with tyrosine kinase inhibitor resistance in chronic myeloid leukemia – a result from a nested Case-Control Study
Nie ZY et al. EJHaem, February 2026 – open access publication
https://buff.ly/Mv59jvP

📖 Explore the full list of papers on our website:
https://buff.ly/9DoiXTp

One more day to go!The iCMLf Climb for a Cure team have spent the past week trekking through the Andes, climbing at alti...
06/03/2026

One more day to go!

The iCMLf Climb for a Cure team have spent the past week trekking through the Andes, climbing at altitude and pushing themselves step by step toward the final summit.

Every step supports the global work of the iCMLf to improve care and outcomes for people living with CML around the world.

There’s still time to sponsor the climbers before they finish tomorrow.

🔗 Support the climb: https://buff.ly/BL7oTvn

Thanks to our sponsors: Terns, Novartis , Enliven, Ascentage, SAHMRI

First summit reached!Today the iCMLf Climb for a Cure team reached their first summit at 4,200 metres in the Andes.It wa...
04/03/2026

First summit reached!

Today the iCMLf Climb for a Cure team reached their first summit at 4,200 metres in the Andes.

It was a tough climb - the altitude makes every step harder. But the whole team pushed through and everyone made it to the top! A powerful start to the journey, and a reminder that progress often comes one difficult step at a time.

Thank you to everyone supporting the climb and the work of the iCMLf.

You can still support the team here: https://buff.ly/BL7oTvn

Thanks to our sponsors: Terns, Novartis, Enliven, Ascentage, SAHMRI

04/03/2026

📣 REMINDER! CALL FOR ABSTRACT!
Take part in the scientific program and showcase your work to the CML community at
the ESH- 28th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
October 2-4, 2026 / Gothenburg, Sweden
Chairs: Jorge Cortes, Tim P. Hughes, Daniela S. Krause
To proceed and for more information 👉 bit.ly/47owRrl

International CML Foundation British Society for Haematology Sociedade Portuguesa de Hematologia

New CML Paper Summary now available.In “How I evaluate and treat resistance and relapse in chronic myeloid leukemia” (So...
03/03/2026

New CML Paper Summary now available.

In “How I evaluate and treat resistance and relapse in chronic myeloid leukemia” (Soverini & Castagnetti, Blood, January 2026), the authors outline a practical, milestone-driven approach to defining resistance, integrating BCR::ABL1 mutation testing, and applying rational TKI sequencing to optimise long-term outcomes.

A clear, clinically grounded roadmap for navigating resistance in the multi-TKI era.

Read the full summary here: https://buff.ly/dRVBVMh

Address

Bexhill

Website

Alerts

Be the first to know and let us send you an email when International CML Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category